A Phase 2 Study Comparing the Safety and Ocular Hypotensive Efficacy of Netarsudil (AR-13324) to Latanoprost in Patients With Elevated Intraocular Pressure

Trial Profile

A Phase 2 Study Comparing the Safety and Ocular Hypotensive Efficacy of Netarsudil (AR-13324) to Latanoprost in Patients With Elevated Intraocular Pressure

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jun 2016

At a glance

  • Drugs Netarsudil (Primary) ; Latanoprost
  • Indications Ocular hypertension; Open-angle glaucoma
  • Focus Therapeutic Use
  • Sponsors Aerie Pharmaceuticals
  • Most Recent Events

    • 02 Dec 2014 Primary endpoint has been met (mean intraocular pressure across subjects measured on each day at each post-treatment timepoint, excluding days 29 and 30), according to an Aerie Pharmaceuticals media release.
    • 02 Dec 2014 Results published in an Aerie Pharmaceuticals media release.
    • 26 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top